林克江，药物化学教授，博士生导师。获中国药科大学药物化学硕士、博士学位，美国加州大学尔湾分校访问****。从事新药研究与开发的教学与科研工作，专注于利用人工智能及计算机辅助药物设计手段，设计并发现具有自主知识产权的全新药物。
研究方向：
针对重大疾病的创新药物研究及创新性先导化合物的发现方法研究。利用深度学习设计小分子活性化合物、理解大分子与小分子相互作用，探索新药发现的新途径。利用计算机辅助药物设计手段研究重大疾病的相关靶标结构与活性关系，发现具有潜力的先导化合物及创新药物。主持及参加了多项省、国家级自然科学基金项目、重大新药创制等科研项目，获得了多项药物专利授权及先导化合物发现新技术专利授权，并在国内、国际期刊上发表学术论文数十篇。
https://orcid.org/0000-0001-6351-5683
https://www.scholarmate.com/P/link
联系方式：link@cpu.edu.cn
近三年（2018-2020）发表论文：
1.Li, X.;Xu, Y.;Yao, H.; Lin, K., Chemical Space Exploration Based on Recurrent Neural Networks: Applications in Discovering Kinase Inhibitors. Journal of Cheminformatics 2020,12(42), 1-13.
2.Dai, Y.;Xu, Y.;Guo, C.;Xue, X.;Lin, D.; Lin, K., Discovery and evaluation of new compounds targeting ribosomal protein S1 in antibiotic-resistant Mycobacterium Tuberculosis. Eur. J. Med. Chem. 2020,196, 112317.
3.Chen, P.;Xu, Y.;Li, X.;Yao, H.; Lin, K., Development and strategies of CDK4/6 inhibitors. Future Med Chem 2020,12(2), 127-145.
4.Shan, W.;Li, X.;Yao, H.; Lin, K., Convolutional Neural Network based Virtual Screening. Curr. Med. Chem. 2020,27, 1-14.
5.Yi, S.;Lin, K.;Jiang, T.;Shao, W.;Huang, C.;Jiang, B.;Li, Q.; Lin, D., NMR-based metabonomic analysis of HUVEC cells during replicative senescence. Aging (Albany NY) 2020,12(4), 3626-3646.
6.Zhang, T.;Huang, F.;Li, B.;Huang, C.;Xu, C.;Lin, K.; Lin, D., NMR-based metabolomic analysis for the effects of Huiyang Shengji extract on rat diabetic skin ulcers. J. Ethnopharmacol. 2020, 112978.
7.Zhong, Y.;Li, X.;Zhu, D.;Zhao, N.;Yao, H.; Lin, K., Characteristics of parathyroid hormone-1 receptor agonists and antagonists. Future Medicinal Chemistry 2019,11(8), 817-831.
8.Zhong, Y.;Li, X.;Yao, H.; Lin, K., The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules. Molecules 2019,24(10), 1940.
9.Zhi, Y.;Dai, Y.;Yang, J.;Tan, S.;Lin, D.; Lin, K., Lead compounds and key residues of ribosomal protein S1 in drug-resistant Mycobacterium tuberculosis. Bioorg. Chem. 2019,82, 58-67.
10.Xu, Y.;Li, X.;Yao, H.; Lin, K., Neural networks in drug discovery: current insights from medicinal chemists. Future Med Chem 2019,11(14), 1669-1672.
11.Xu, Y.;Chen, P.;Lin, X.;Yao, H.; Lin, K., Discovery of CDK4 inhibitors by convolutional neural networks. Future Medicinal Chemistry 2019,11(3), 165-177.
12.Ma, L.;Li, X.;Bai, Z.;Lin, X.; Lin, K., AdipoRs- a potential therapeutic target for fibrotic disorders. Expert Opinion on Therapeutic Targets 2019,23(2), 93-106.
13.Xu, Y.;Yao, H.; Lin, K., An overview of neural networks for drug discovery and the inputs used. Expert Opinion on Drug Discovery 2018,13(12), 1091-1102.
14.Song, Z.;Huang, S.;He, Y.;Li, J.;Lin, K.; Xue, X., Synthesis and anti-fibrosis activity study of 14-deoxyandrographolide-19-oic acid and 14-deoxydidehydroandrographolide-19-oic acid derivatives. Eur. J. Med. Chem. 2018,157, 805-816.
15.Chen, X.;Zhang, L.;Zhang, M.;Liu, H.;Lu, P.; Lin, K., Quorum sensing inhibitors: a patent review (2014-2018). Expert Opinion on Therapeutic Patents 2018,28(12), 849–865.
16.Xu, Y.;Tong, X.;Sun, P.;Bi, L.; Lin, K., Virtual screening and biological evaluation of biofilm inhibitors on dual targets in quorum sensing system. Future Medicinal Chemistry 2018,9(17), 1983-1994.
近三年（2018-2020）授权专利：
1.林克江;支运宝; 仲艳雯三类羧基取代芳香化合物在耐吡嗪酰胺结核病及结核病治疗中的医药用途. ZL 2.5, 2020.
2.林克江;代亚庄;马菱曼;张震;叶波平; 薛晓文三个多肽片段在制备抗纤维化药物中的医药用途. **, 2020.
3.林克江;支运宝; 易胜辉四氮唑取代芳香化合物在耐吡嗪酰胺结核病及结核病治疗中的医药用途. ZL3.X, **, 2019.
4.林克江;支运宝; 陈萍萍N-(噻吩-2)酰胺类衍生物在耐吡嗪酰胺结核病及结核病治疗中的医药用途. ZL0.2, 2019.
5.林克江; 徐吟秋基于卷积神经网络的智能化先导化合物发现方法. ZL , **, 2019